Nouscom's Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to 'Intercept' Cancer - The Manila Times
Nouscom's Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to 'Intercept' Cancer The Manila Times
Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation - The Week
Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation The Week